SS, S., & A, K. (2016). Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: Focus on dapagliflozin–metformin. Dove Medical Press.
Style de citation Chicago (17e éd.)SS, Schwartz, et Katz A. Sodium–glucose Cotransporter-2 Inhibitor Combination Therapy to Optimize Glycemic Control and Tolerability in Patients with Type 2 Diabetes: Focus on Dapagliflozin–metformin. Dove Medical Press, 2016.
Style de citation MLA (8e éd.)SS, Schwartz, et Katz A. Sodium–glucose Cotransporter-2 Inhibitor Combination Therapy to Optimize Glycemic Control and Tolerability in Patients with Type 2 Diabetes: Focus on Dapagliflozin–metformin. Dove Medical Press, 2016.
Attention : ces citations peuvent ne pas être correctes à 100%.